Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6):680-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

ORIGINAL ARTICLES  IMAGING OF THERAPY RESPONSE IN ONCOLOGY 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 December;55(6):680-7

Copyright © 2012 EDIZIONI MINERVA MEDICA

lingua: Inglese

Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study

Fuster D. 1, Ayuso J. R. 2, Poveda A. 3, Cubedo R. 4, Casado A. 5, Martínez-Trufero J. 6, López-Pousa A. 7, Del Muro X. G. 8, Lomeña F. 1, Maurel J. 9, Pons F. 1

1 Nuclear Medicine, Hospital Clínic Barcelona, Barcelona, Spain; 2 Department of Radiology, Hospital Clínic Barcelona, Barcelona, Spain; 3 Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain; 4 Medical Oncology, Hospital Puerta de Hierro, Madrid, Spain; 5 Medical Oncology, Hospital Clínico Madrid, Madrid, Spain; 6 Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain; 7 Medical Oncology, Hospital Sant Pau, Spain; 8 Medical Oncology, Institut Català d’Oncologia, Barcelona, Spain; 9 Medical Oncology, Hospital Clínic Barcelona; ID IBAPS, CIBEREHD


PDF


AIM: The aim of this study was to evaluate the utility of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) in monitoring response in refractory GIST.
METHODS: This multicenter study prospectively evaluated 21 patients with locally advanced and/or metastatic GIST refractory to with high-dose imatinib (800 mg/day) treated with doxorubicin 15-20 mg/m2/weekly for 4 cycles, followed by imatinib maintenance (400 mg/day). CT and FDG-PET were performed at baseline and after completion of therapy.
RESULTS:Mean baseline tumor size on CT was 5.9 cm. Median progression-free survival (PFS) was 219 days (range 62-1108). Three out of 21 patients (14%) had partial responses (PR) under RECIST criteria, 12 patients (57%) remained stable (SD) and 6 showed progression (PD) of the disease during treatment (29%). Six patients had PR by FDG-PET, 15 showed SD (n=9) or PD (n=6) based on EORTC criteria. Patients with a PFS <6 mo showed a significantly higher ∑SUVmax at baseline (26.04±13.4) than those with PFS≥6 mo (9.82±5.0) (P<0.05). A correlation was found between PET response and PFS: PR 14±6.1 mo, SD 5.5±0.8 mo and PD 3.5±4.1 mo (P<0.05). A residual SUVmax <5 after treatment correlated with improved PFS (314±315 days vs 131±91 days) (P<0.01). Survival curves showed a significant association between PET response and PFS (P<0.05). Patients with wild-type genotype KIT (KIT-WT) showed a significantly lower baseline SUVmax (5.36±1.4) than non-WT KIT (8.40±3.6) (P<0.05).
CONCLUSION:FDG-PET is useful in assessing response of GIST refractory to imatinib and correlates with the presence of KIT-WT. Baseline ∑SUVmax can predict response to treatment in this series.

inizio pagina